Burzynski Research Institute, Inc. Announces Publication of Phase 2 Clinical Study in Metastatic Colon Adenocarcinoma of the Liver

HOUSTON, March 26, 2015 /PRNewswire/ -- The Burzynski Research Institute, Inc. (BRI) announced today that results of a study independently conducted by the Department of Surgery at Kurume University Medical Center in Japan have been published. The study, a randomized non-blinded phase 2 trial, compared 5-fluorouracil hepatic arterial infusion as post-operative adjuvant therapy with and without Antineoplastons A10/AS2-1 Injections for colorectal metastasis of the liver.

A total of 65 patients, with histologically confirmed metastatic colon adenocarcinoma of the liver, were evaluated. Primary endpoints included cancer-specific survival. Secondary endpoints included relapse-free survival, clinical status and extent of recurrence, salvage surgery rate and toxicity.

BRI believes that the completion of the study represents an important milestone in the development of Antineoplastons and that further efficacy trials of Antineoplastons in colorectal cancer should continue to be pursued.

About Burzynski Research Institute, Inc.
Burzynski Research Institute, Inc. (OTCBB:BZYR) is a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles.  Research and development efforts are focused on basic research and phase 3 clinical trials, particularly in the treatment of brain tumors and other forms of cancer.

SOURCE Burzynski Research Institute, Inc.